Prothena (PRTA) Stock Forecast & Price Target $9.83 +0.42 (+4.46%) Closing price 04:00 PM EasternExtended Trading$9.57 -0.26 (-2.63%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Prothena - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 11 Analyst RatingsSell2Hold4Buy5 Based on 11 Wall Street analysts who have issued ratings for Prothena in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 2 have given a sell rating, 4 have given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for PRTA. Consensus Price Target $21.78121.54% Upside According to the 11 analysts' twelve-month price targets for Prothena, the average price target is $21.78. The highest price target for PRTA is $36.00, while the lowest price target for PRTA is $6.00. The average price target represents a forecasted upside of 121.54% from the current price of $9.83. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for PRTA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Prothena and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTA Analyst Ratings Over TimeTypeCurrent Forecast5/22/25 to 5/22/261 Month Ago4/22/25 to 4/22/263 Months Ago2/21/25 to 2/21/261 Year Ago5/22/24 to 5/22/25Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)Buy4 Buy rating(s)4 Buy rating(s)4 Buy rating(s)5 Buy rating(s)Hold4 Hold rating(s)4 Hold rating(s)4 Hold rating(s)2 Hold rating(s)Sell2 Sell rating(s)2 Sell rating(s)2 Sell rating(s)0 Sell rating(s)Consensus Price Target$21.78$21.67$22.00$51.71Forecasted Upside121.54% Upside102.11% Upside143.90% Upside689.53% UpsideConsensus RatingHoldHoldHoldModerate Buy PRTA Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History PRTA Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Prothena Stock vs. The CompetitionTypeProthenaMedical CompaniesBroader MarketConsensus Rating Score 2.36 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside121.54% Upside1,715.38% Upside15.04% UpsideNews Sentiment RatingNeutral NewsSee Recent PRTA NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/14/2026 Weiss RatingsNot Rated UpgradeSell (E+) ➝ Sell (D-)5/8/2026 Citigroup4 of 5 stars Reiterated RatingOutperform5/8/2026 Citizens Jmp4 of 5 starsJason N.Not RatedBoost TargetMarket Outperform$19.00 ➝ $20.00+84.42%3/13/2026 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$19.00+104.08%2/20/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian AbrahamsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetSector Perform$11.00 ➝ $12.00+35.98%12/1/2025 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$19.00+76.83%11/19/2025 Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRudy LiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy11/7/2025 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrew S.Subscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$20.00 ➝ $30.00+194.41%10/28/2025 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$36.00+223.65%10/28/2025 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYasmeen RahimiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$15.00 ➝ $36.00+247.16% Get the Latest News and Ratings for PRTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. 6/20/2025 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEric SchmidtSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingNeutral5/28/2025 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTazeen AhmadSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeBuy ➝ Hold$6.00-8.81%5/27/2025 OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJay OlsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Market PerformAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:11 PM ET. PRTA Forecast - Frequently Asked Questions What is Prothena's forecast for 2026? According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Prothena is $21.78, with a high forecast of $36.00 and a low forecast of $6.00. Should I buy or sell Prothena stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 2 sell ratings, 4 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTA, but not buy additional shares or sell existing shares. Does Prothena's stock price have much upside? According to analysts, Prothena's stock has a predicted upside of 121.54% based on their 12-month stock forecasts. Has Prothena been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Prothena's stock had 1 upgrade and 1 downgrade by analysts. What analysts cover Prothena? Prothena has been rated by research analysts at Citigroup, Citizens Jmp, Stifel Nicolaus, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Prothena more than its competitors? Analysts like Prothena more than other "medical" companies. The consensus rating score for Prothena is 2.36 while the average consensus rating score for "medical" companies is 2.30. Learn more on how PRTA compares to other companies. Stock Forecasts and Research Tools Related Companies Ocular Therapeutix Stock Forecast Pharvaris Stock Forecast Aurinia Pharmaceuticals Stock Forecast Mesoblast Stock Forecast ADMA Biologics Stock Forecast Intellia Therapeutics Stock Forecast Stoke Therapeutics Stock Forecast AnaptysBio Stock Forecast Ascentage Pharma Group International Stock Forecast Sionna Therapeutics Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Prothena RecommendationsWeiss RatingsCitizens JmpCitigroupStifel NicolausRoyal Bank Of CanadaDeutsche Bank AktiengesellschaftChardan CapitalWall Street ZenHC WainwrightPiper SandlerUBS GroupCantor FitzgeraldBank of AmericaOppenheimerJefferies Financial Group This page (NASDAQ:PRTA) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredJune 12: Elon Musk’s “Day-One Retirement Plan.”SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredI don't think Wall Street will warn you in timeWall Street insiders move early. Everyone else finds out later. That gap gets especially dangerous during a Ch...Trend Labs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
